Company
Cancer Institute Gustave Roussy, , 
Bio

JP Armand focuses his cancer research in the field of new mechanism of oncogenes’ and early drug development.

Jean-Pierre Armand MD, MSc, is certified in Medical Oncology (University of Toulouse III and Paris XI)

He was recently General Director of the Institut Claudius Regaud in Toulouse  . Over the last five years he has been in charge of the construction of a new cancer center, in a European research hub created in the Toulouse cancer campus (Institut Universitaire du Cancer)and opened in 2014.

After a position as research fellow in Columbia University New York, Dr Armand has joined Institut Claudius Regaud in Toulouse, he was head of Medical oncology until 1984. In the next 23 years, at Institut Gustave Roussy (IGR) in Paris, he was successively CEO of the Hospital IGR3, head of the Department of Medical oncology at IGR2 and finally CMO of IGR&D, Dept of Innovation and Development at IGR.

Although expert in breast, head&neck, and neuro-oncology, the first field of Dr Armand was very early drug development in phase 1 and 2 of new anticancer agents . He is  the founder of the IGR Phase I Unit (Ditep) in the early 80s.  He did the first in human phase I in the world at IGR of numerous drugs, now used routinely, including classicals cytotoxics,topo2 inhibitors, Irinotecan, Oxaliplatin, Taxotere, Navelbine, Vinflunine, and more recently targeted therapies, Sutent, Sorafenib, Temsirolimus...

At present ,he and his colleagues are concentrating in Gustave Roussy DITEP  on new therapies for orphan treatment cancer diseases, with a special personal  investment in  cancer biotechs .